<DOC>
	<DOCNO>NCT00193518</DOCNO>
	<brief_summary>Additional active agent need improve treatment patient CLL/SLL . Increasing information exist regard activity arsenic trioxide hematologic malignancy . Since arsenic trioxide produce mild moderate myelosuppression immunosuppressive available agent , may additional treatment option CLL/SLL . This study evaluate feasibility toxicity arsenic trioxide patient relapse refractory CLL/SLL</brief_summary>
	<brief_title>Arsenic Trioxide Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Arsenic Trioxide</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>To include study , must meet following criterion : Histologically proven Bcell CLL/SLL . Must minimum 1 maximum 3 previous systemic regimen Must progressive CLL/SLL Measurable evaluable disease ECOG performance status 0 , 1 , 2 Age &gt; 18 year . Patients cytopenias cause bone marrow involvement eligible All patient must give write informed consent prior enter study . You participate study follow apply : Unstable active infection basis neutropenia Previous severe opportunistic infection Severe immune mediate anemia thrombocytopenia Serious underlie medical condition Brain metastasis meningeal involvement History neoplasm Significant underlying heart dysfunction Women pregnant Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>